Pathologic 'fused gland' as a prognostic factor for prostate cancer.
We examined the significance of a pathologic 'fused gland' according to the WHO-Mostofi classification for predicting prognosis in hormonally treated prostate cancer. Of 284 newly diagnosed patients receiving hormone therapy, 60 patients had specimens with no 'medullary' or 'column-cord' elements. Twenty-five of these had a 'fused gland', while 35 did not. Survival of these patients was analyzed. Cause-specific survival of the patients with no medullary or column-cord elements showed a significantly better prognosis compared to others. Furthermore, the patients whose specimens contained a 'fused gland' component had significantly poorer survival than those without that component, suggesting that the 'fused gland' component is a poor prognostic factor for survival in patients with hormonally treated prostate cancer.
Noguchi
S
S
Department of Urology, Yohokama City University School of Medicine, Yokohama, Japan. rn1009@yellow.med.yokohama-cu.ac.jp
Kubota
Y
Y
Kondoh
I
I
Harada
M
M
Masuda
M
M
Uemura
H
H
Hosaka
M
M
D000230:Adenocarcinoma / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology*; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology*; D015996:Survival Rate
D018931:Antineoplastic Agents, Hormonal